More on RARE
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $25.21 |
|
|||
| Open | $25.22 | ||||
| 52 Wk High | $117.12 | ||||
| 52 Wk Low | $46.52 | ||||
| Day High | $25.85 | ||||
| Day Low | $25.11 | ||||
| P/E | N/A | ||||
| EPS | $-1.97 | ||||
| Volume | 1,871,231 | ||||
- Ultragenyx publishes 96-week phase 3 data for GSDIa gene therapy
- Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journ
- Ultragenyx Pharma (RARE) PT Raised to $50 at Wells Fargo
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Pharma (RARE) PT Raised to $80 at JPMorgan
- Ultragenyx Pharma (RARE) PT Raised to $74 at Morgan Stanley
- H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)
- Ultragenyx Pharma (RARE) PT Raised to $46 at Wells Fargo
- Ultragenyx Pharma (RARE) PT Raised to $83 at Canaccord
- Citi raises Ultragenyx price target to $58 after FDA approval
Entities mentioned with RARE
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Cowen & Co | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
